Grasp the new situation of transformation and upgrading and meet the new opportunities for the development of pharmaceutical industry

Source: bioexploration 2015-4-14 China Health Investment Summit (CHIC) held by consortium of China healthcare and hosted by lychee group on April 1, 2015 ）Held in Shanghai, opinion leaders from top investment banks, public and private venture capitalists, domestic and foreign medical industry giants and government service departments with great voice in the industry gathered to discuss and compare the investment risk and return rate in the Chinese and foreign markets Mr Zhu Hongren, former member of the Party group and chief engineer of the Ministry of industry and information technology of the people's Republic of China, gave a wonderful speech to the guests at the meeting, "grasp the new situation of transformation and upgrading, and meet the new opportunities for the development of the pharmaceutical industry" In the context of the new situation, new trend and new opportunities, he called on all parties involved in the pharmaceutical industry to strengthen cooperation and share experience In his opinion, it's not spring for a big health industry to be a single flower Only a myriad of colors can make a garden full of spring Zhu Hongren's new situation: in 2014, the operation of China's pharmaceutical industry faced new challenges in the development of the pharmaceutical industry In the environment of domestic macro-economic growth turning into a "new normal" and slowing down in growth, the development pace of the pharmaceutical industry in 2014 also shifted and slowed down accordingly, entering the transformation period of structural adjustment Due to the overcapacity of some products, the decline of market price, the failure of GMP certification and environmental protection restrictions of some enterprises, as well as the unreasonable use of drugs under the control of medical insurance fees and other factors, the pharmaceutical industry experienced a decline in production and sales, the continuous downturn in the export market, and further decline in the growth rate of main business income and total profits The development of the pharmaceutical industry has stepped into a period of transformation and upgrading First, the proportion of the output of the pharmaceutical industry in the industrial industry continues to increase In 2014, the added value of the pharmaceutical industry increased by 12.5% year-on-year Although the growth rate decreased by 0.2% year-on-year, it was still 4.2% higher than the average level of the industry, accounting for 2.8% of the national industry, and kept improving for many years Second, the growth rate of income and profit continued to grow rapidly The main business income of Enterprises above the scale of pharmaceutical industry is 245.5316 billion yuan, up 13.05% year on year, down 4.85 percentage points from last year, still higher than the average growth rate of national industry by 6.05 percentage points The total profit of Pharmaceutical Enterprises above Designated Size reached 246.069 billion yuan, an increase of 12.26% year on year, 8.96 percentage points higher than the national industrial average, and 5.34 percentage points lower than last year's growth rate The profit margin of the pharmaceutical industry for the whole year was 10.02%, down 0.1 percentage points from last year, but still 4.1 percentage points higher than the national industrial average Third, the pace of medicine export has been accelerated In the whole year, pharmaceutical enterprises above Designated Size achieved export delivery value of 174081 million yuan, a year-on-year increase of 6.63% Although the growth rate is not high compared with the previous years, it is 0.83 percentage points higher than that in 2013 According to the import and export data of the customs, the export volume of pharmaceutical products is US $55 billion, up 7.4% year on year, 0.6% higher than that in 2013 Fourth, focus on fixed asset investment In the whole year, the fixed asset investment of the pharmaceutical manufacturing industry reached 520.5 billion yuan, an increase of 15.1% year-on-year, a significant decline compared with the growth rate of 26.5% last year, but still 1.6 percentage points higher than the average level of the manufacturing industry The focus of enterprise investment has gradually shifted from GMP upgrading and transformation to the industrialization of new products and the construction of new plant areas To speed up the pace of structural adjustment of pharmaceutical enterprises, the first is to enhance the ability of drug supply guarantee According to the statistics of the State Food and drug administration, in 2014, the new version of GMP certification was steadily promoted in China The pass rate of sterile drug manufacturers was 70%, and that of non sterile drug manufacturers was 60% The pass rate of new version GMP certification of top 100 pharmaceutical industry sales revenue enterprises reached more than 90% The reform and implementation of the price management mode of some low-cost drugs priced by the government, and the cancellation of the maximum retail price limit of 533 low-cost drugs, have taken an important step towards price marketization, which is conducive to the enhancement of the supply guarantee ability of commonly used low-cost drugs The first four national bidding pilot projects for designated production of drugs in short supply organized by the Ministry of industry and information technology were launched and successfully implemented, and the supply of some drugs in short supply, such as methimazole, was effectively guaranteed In 2014, the pace of international registration of pharmaceutical preparations of our pharmaceutical enterprises was faster and faster, and the number of products declared through the Anda of the United States increased by 8 Second, there are more innovative R & D enterprises In 2014, the number of new drug applications accepted by the State Food and drug administration increased significantly, with a year-on-year increase of 18.7%; the number of new drugs approved for clinical use and class 3.1 chemicals increased significantly, with 52.2% and 103.5% respectively A class of key new drugs with production approval are: apatinib mesylate, a small molecule targeted anti-tumor drug independently developed by Jiangsu Hengrui, independently developed by Shenzhen micro core biology, and xidaban, an anti-tumor drug with new chemical structure, etc The independent innovation of medical devices has achieved positive results, and the third generation of coronary targeted elution (TES) stent system for coronary heart disease interventional therapy independently developed by Shanghai minimally invasive technology Co., Ltd has been approved for listing Third, there has been an increase in industry merger and reorganization The State Council's opinions on further optimizing the market environment of enterprise merger and reorganization put forward to reduce the administrative examination and approval matters related to merger and reorganization, and provide financial and tax policy support for merger and reorganization The merger and reorganization of the pharmaceutical industry continues to remain active According to incomplete statistics, there were more than 200 pharmaceutical merger and acquisition projects among domestic enterprises in 2014, with a transaction amount of more than 50 billion yuan, and the number and amount of transactions equivalent to 5-7 times of 2009 The large-scale ones include: Shanghai Laishi acquired Tonglu biology with RMB 4.758 billion, LVYE pharmaceutical acquired Beijing Jialin pharmaceutical with RMB 3.684 billion, Yuheng pharmaceutical acquired Shanxi Pude pharmaceutical with RMB 2.38 billion, etc In 2014, 18 listed companies in the pharmaceutical industry were listed in the top 500 in China M & A plays an important role in promoting pharmaceutical companies to increase product lines, expand industrial chain and enhance competitiveness Fourth, the development of small and medium-sized enterprises is more active The growth share of the main business income and total profit of large-scale enterprises accounts for more than one third of the industry; the growth rate of the main business income and total profit of small and medium-sized enterprises accounting for 96.1% is higher than the industry average, 13.4% and 14.8% respectively, and the growth contribution of small and medium-sized enterprises is more than double that of large enterprises New trend: the development of China's pharmaceutical industry in 2015 is looking forward to the fact that the internal and external driving forces for the pharmaceutical industry to actively adapt to the new normal economic development in 2015 are still sustained, and the pharmaceutical industry is expected to maintain the rapid growth momentum in 2014 throughout the year In view of the challenges and problems in the development, we need to focus on improving the operation quality and economic benefits, accelerate innovation driven, transformation and upgrading, scientifically tap the potential of consumption growth, actively implement resource integration and reorganization, effectively resolve overcapacity, increase the international operation and promote the sustainable and healthy development of the pharmaceutical market The steady growth of the pharmaceutical industry is still expected First, the macro situation is stable and the rigid demand is increasing In 2015, the global economy will recover further slowly China's GDP growth target is 7%, which is generally conducive to the steady development of the pharmaceutical market There are nearly 10 million new aged people over 60 years old in China every year The per capita medical expenses of the aged are 3-5 times higher than that of the young There is a huge demand potential in the medical market for the aged Second, the investment in medical reform effectively drives market growth In 2015, the annual per capita investment of government finance and individuals in the new rural cooperative medical insurance fund and urban residents' medical insurance fund reached more than 500 yuan, an increase of 22%, a year-on-year increase of 5 percentage points, "Three Guarantees integration" pilot expansion, combined with the medical consumption brought by the new urbanization, it is estimated that each year is close to 20 billion yuan, which will effectively promote the release of medical and health care needs Third, the reform of capital market should create a better environment In 2014, a number of pharmaceutical enterprises with good growth, such as Kyushu pharmaceutical, Changchun Dirui, sunflower pharmaceutical, etc., successively went public to obtain development funds In 2015, the implementation of the stock issuance registration system reform in the securities market is expected to speed up the pilot At present, more than 50 pharmaceutical enterprises are in the stage of IPO review, and many growing enterprises are facing the favorable opportunity of expanding financing channels and realizing rapid development Fourth, the State supports the improvement of technological innovation In 2014, the major science and technology project of "major new drug creation" was implemented in-depth Through improving the project performance evaluation and post implementation subsidy special support mode, we focused on supporting innovative drug research and key core technology research to solve bottleneck problems for 10 categories (species) of major diseases seriously endangering people's health The special projects for the development of high and new technologies such as biological protein medicine, vaccine and high-end medical equipment, as well as the support projects for the modern Chinese medicine planting base, continue to receive strong support from the national innovation special funds Fifth, the industrial development environment has been constantly optimized In 2014, major breakthroughs were made in comprehensively deepening reform, with more than 300 administrative approvals cancelled and delegated by the State Council throughout the year The cancellation of the minimum registered capital and investment period, and the establishment of a negative list of market access have greatly stimulated the vitality of market entrepreneurship In 2015, a series of important reforms, such as the marketization of drug prices, the mixed ownership of state-owned enterprises, and the optimization of fiscal and tax policies, will indeed continue to be improved The government's supervision on environmental protection and compliance management will be strengthened, which will be more conducive to fair market competition New opportunities: to grasp the development opportunities of the pharmaceutical industry, we should pay attention to the industrial economic policy orientation First, to speed up the system reform and release the strong vitality of the pharmaceutical industry to create supply Recently, the CPC Central Committee and the general office of the State Council issued the guiding opinions on the implementation of the power list system of local government departments at all levels, vigorously deepening the reform of the administrative system The reform of drug and medical device evaluation and approval system, which is widely concerned by pharmaceutical enterprises, is speeding up The second is to provide an inexhaustible power for the sustainable development of the pharmaceutical industry by accelerating innovation The general office of the State Council issued several opinions on innovation of investment management mode and establishment of collaborative supervision mechanism, deployed to establish a vertical and horizontal linkage collaborative supervision mechanism for investment projects, strengthened supervision during and after investment projects, and standardized investment behavior and market order; 2015 In, the state will continue to focus on supporting innovative drug research and key core technology research on major diseases, and will support the industrialization of high-end manufacturing and the transformation of key core technology The third is to stimulate the great potential of transformation and upgrading of the pharmaceutical industry by strengthening integration 1 Integration of industry and finance The Central Committee of the Communist Party of China and the State Council issued several opinions on deepening the reform of system and mechanism and accelerating the implementation of innovation driven development strategy, which put forward to strengthen the function of financial innovation, cultivate and expand venture capital and capital market, strengthen the support of capital market for technological innovation, broaden the indirect financing channels of technological innovation, and play an important role in promoting the sound and rapid development of pharmaceutical market investment Make sense 2 Integration of the two On March 25, the executive meeting of the State Council arranged to accelerate the implementation of "made in China 2025" and realize the upgrading of manufacturing industry; to follow the development trend of "Internet +", take the deep integration of informatization and industrialization as the main line, focus on the development of 10 major areas including biomedicine and high-performance medical devices, and strengthen